{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:59:08Z","timestamp":1791460748497,"version":"4.3.4"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) have shown significant cardiovascular benefits in patients with and without type 2 diabetes mellitus (T2DM). They have also gained interest for their potential anti-arrhythmic role and their ability to reduce the occurrence of atrial fibrillation (AF) and ventricular arrhythmias (VAs) in T2DM and heart failure patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate in-hospital new-onset cardiac arrhythmias in a cohort of T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-i vs. other oral anti-diabetic agents (non-SGLT2-i users).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients from the SGLT2-I AMI PROTECT registry (NCT05261867) were stratified according to the use of SGLT2-i before admission for AMI, divided into SGLT2-i users vs. non-SGLT2-i users. In-hospital outcomes included the occurrence of in-hospital new-onset cardiac arrhythmias (NOCAs), defined as a composite of new-onset AF and sustained new-onset ventricular tachycardia (VT) and\/or ventricular fibrillation (VF) during hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study population comprised 646 AMI patients categorized into SGLT2-i users (111 patients) and non-SGLT2-i users (535 patients). SGLT2-i users had a lower rate of NOCAs compared with non-SGLT2-i users (6.3 vs. 15.7%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.010). Moreover, SGLT2-i was associated with a lower rate of AF and VT\/VF considered individually (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.032). In the multivariate logistic regression model, after adjusting for all confounding factors, the use of SGLT2-i was identified as an independent predictor of the lower occurrence of NOCAs (OR = 0.35; 95%CI 0.14\u20130.86;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.022). At multinomial logistic regression, after adjusting for potential confounders, SGLT2-i therapy remained an independent predictor of VT\/VF occurrence (OR = 0.20; 95%CI 0.04\u20130.97;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.046) but not of AF occurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In T2DM patients, the use of SGLT2-i was associated with a lower risk of new-onset arrhythmic events during hospitalization for AMI. In particular, the primary effect was expressed in the reduction of VAs. These findings emphasize the cardioprotective effects of SGLT2-i in the setting of AMI beyond glycemic control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Data are part of the observational international registry: SGLT2-I AMI PROTECT.\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , identifier: NCT05261867.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2022.1012220","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T01:23:49Z","timestamp":1664241829000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":77,"title":["In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study"],"prefix":"10.3389","volume":"9","author":[{"given":"Arturo","family":"Cesaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Gragnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Paolisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Gallinoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestino","family":"Sardu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niya","family":"Mileva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Armillotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Sansonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Amicone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Impellizzeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuccia","family":"Morici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo Andrea","family":"Oreglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Casella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dobrin","family":"Vassilev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Galie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Santulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Pizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Marfella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1093\/europace\/euz163","article-title":"Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA)","volume":"21","author":"Kalarus","year":"2019","journal-title":"EP Eur."},{"key":"B2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1161\/CIR.0000000000000549","article-title":"2017 AHA\/ACC\/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.hrthm.2011.06.036","article-title":"Ischemic ventricular arrhythmias: Experimental models and their clinical relevance","volume":"8","author":"Di Diego","year":"2011","journal-title":"Hear Rhythm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fcvm.2019.00158","article-title":"Ventricular arrhythmias in first acute myocardial infarction: epidemiology, mechanisms, and interventions in large animal models","volume":"6","author":"Sattler","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1009388","DOI":"10.1371\/journal.pcbi.1009388","article-title":"Mechanisms of ventricular arrhythmias elicited by coexistence of multiple electrophysiological remodeling in ischemia: a simulation study","volume":"18","author":"Liang","year":"2022","journal-title":"PLoS Comput Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.110.990192","article-title":"Atrial fibrillation and death after myocardial infarction","volume":"123","author":"Jabre","year":"2011","journal-title":"Circulation."},{"key":"B8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.ahj.2005.05.015","article-title":"Ventricular arrhythmias after acute myocardial infarction: a 20-year community study","volume":"151","author":"Henkel","year":"2006","journal-title":"Am Heart J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.5603\/KP.2018.0041","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.amjcard.2011.10.043","article-title":"Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial)","volume":"109","author":"Mehta RH Yu","year":"2012","journal-title":"Am J Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2018.10.007","article-title":"Twenty-five year trends (1986-2011) in hospital incidence and case-fatality rates of ventricular tachycardia and ventricular fibrillation complicating acute myocardial infarction","volume":"208","author":"Tran H","year":"2019","journal-title":"Am Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCULATIONAHA.111.023838","article-title":"Epidemiology and genetics of sudden cardiac death","volume":"125","author":"Deo","year":"2012","journal-title":"Circulation."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.jacc.2022.03.353","article-title":"Sodium glucose cotransporter-2 inhibition for acute myocardial infarction","volume":"79","author":"Udell","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B14","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"154936","DOI":"10.1016\/j.metabol.2021.154936","article-title":"Sodium\/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts","volume":"127","author":"Marfella","year":"2022","journal-title":"Metabolism."},{"key":"B18","doi-asserted-by":"publisher","first-page":"777083","DOI":"10.3389\/fphar.2021.777083","article-title":"Effects of sodium-glucose transporter 2 inhibitors (SGLT2-I) in patients with Ischemic Heart Disease (IHD) treated by coronary artery bypass grafting via MiECC: inflammatory burden, and clinical outcomes at 5 years of follow-up","volume":"12","author":"Sardu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155243","article-title":"SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study","volume":"155243","author":"Sardu","year":"2022","journal-title":"Metabolism"},{"key":"B20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/dom.13512","article-title":"Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies","volume":"21","author":"Bell","year":"2019","journal-title":"Diabetes Obes Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.15420\/aer.2017.24.1","article-title":"Ventricular arrhythmia after acute myocardial infarction: \u2018The Perfect Storm'","volume":"6","author":"Bhar-Amato","year":"2017","journal-title":"Arrhythmia Electrophysiol Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3390\/ijms23031678","article-title":"SGLT2 inhibitors and their antiarrhythmic properties","volume":"23","author":"Kolesnik","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"902923","DOI":"10.3389\/fcvm.2022.902923","article-title":"Effect of Sodium-Glucose Co-transporter protein 2 inhibitors on arrhythmia in heart failure patients with or without type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"9","author":"Yin","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2022.04.003","article-title":"Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias","author":"Manolis","year":"2022","journal-title":"Trends Cardiovasc Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","article-title":"Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry","volume":"21","author":"Paolisso","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/2047487318755531","article-title":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","volume":"25","author":"Usman","year":"2018","journal-title":"Eur J Prev Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0244689","DOI":"10.1371\/journal.pone.0244689","article-title":"Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis","volume":"16","author":"Li","year":"2021","journal-title":"PLoS ONE."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/dom.13627","article-title":"Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: a nationwide observational study","volume":"21","author":"Norhammar","year":"2019","journal-title":"Diabetes Obes Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/dom.13077","article-title":"Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observationa","volume":"20","author":"Persson","year":"2018","journal-title":"Diabetes, Obes Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation."},{"key":"B32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12933-020-01162-w","article-title":"The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors","volume":"19","author":"Ling","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e022222","DOI":"10.1161\/JAHA.121.022222","article-title":"Sodium-Glucose Co-Transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Pandey","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Hear Rhythm."},{"key":"B35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","article-title":"Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease","volume":"52","author":"Zhou","year":"2021","journal-title":"Stroke."},{"key":"B37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/jpm12020271","article-title":"Clinical observation of SGLT2 inhibitor therapy for cardiac arrhythmia and related cardiovascular disease in diabetic patients with controlled hypertension","volume":"12","author":"Jhuo","year":"2022","journal-title":"J Pers Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12933-022-01508-6","article-title":"Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus","volume":"21","author":"Suzuki","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur Heart J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1002\/ehf2.13553","article-title":"Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial","volume":"8","author":"Ilyas","year":"2021","journal-title":"ESC Hear Fail."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e024260","DOI":"10.1161\/JAHA.121.024260","article-title":"Prognostic significance of ventricular arrhythmias in 13 444 patients with acute coronary syndrome: a retrospective cohort study based on routine clinical data (NIHR Health Informatics Collaborative VA-ACS Study)","volume":"11","author":"Sau","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-020-01048-x","article-title":"The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study","volume":"19","author":"Chen","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.21203\/rs.3.rs-35207\/v2","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/fendo.2018.00421","article-title":"The effects of Sodium-Glucose cotransporter 2 inhibitors on sympathetic nervous activity","volume":"9","author":"Wan","year":"2018","journal-title":"Front Endocrinol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jacbts.2020.01.011","article-title":"Are the cardiorenal benefits of SGLT2 inhibitors due to inhibition of the sympathetic nervous system?","volume":"5","author":"Verma","year":"2020","journal-title":"JACC Basic to Transl Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/0885066609340519","article-title":"Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress","volume":"24","author":"D\u00fcnser","year":"2009","journal-title":"J Intensive Care Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12933-018-0779-8","article-title":"Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction","volume":"17","author":"Tran H","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.biocel.2019.01.004","article-title":"Sympathetic nervous system in age-related cardiovascular dysfunction: pathophysiology and therapeutic perspective","volume":"108","author":"de Lucia","year":"2019","journal-title":"Int J Biochem Cell Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s001250051345","article-title":"The effect of acute hyperglycaemia on QTc duration in healthy man","volume":"43","author":"Marfella","year":"2000","journal-title":"Diabetologia."},{"key":"B50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1530\/EJE-21-0232","article-title":"Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls","volume":"185","author":"Andersen","year":"2021","journal-title":"Eur J Endocrinol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation."},{"key":"B52","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","article-title":"SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats","volume":"17","author":"Durak","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Hear Fail."},{"key":"B54","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.3390\/ijms22157976","article-title":"Cardioprotection by SGLT2 inhibitors\u2014does it all come down to Na+?","volume":"22","author":"Trum","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12933-021-01392-6","article-title":"Empagliflozin protects the heart against ischemia\/reperfusion-induced sudden cardiac death","volume":"20","author":"Hu","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"119440","DOI":"10.1016\/j.lfs.2021.119440","article-title":"Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia","volume":"276","author":"Azam","year":"2021","journal-title":"Life Sci."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1012220\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T01:23:53Z","timestamp":1664241833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1012220\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":56,"alternative-id":["10.3389\/fcvm.2022.1012220"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1012220","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"article-number":"1012220"}}